In Competitive RSV Market, GSK Aims To Be First For Adults 50-59

 
• By Jessica Merrill and Sarah Karlin-Smith

Results from a Phase III trial testing the RSV vaccine Arexvy in adults 50-59 met the two primary endpoints, potentially opening the door to a wider adult market.

building blocks
GSK is hoping to build out the label for its RSV vaccine • Source: Shutterstock

More from Anti-infective

More from Therapy Areas